Last updated: February 20, 2026
What are the scope and claims of EP3409273?
EP3409273 pertains to a novel pharmaceutical invention related to methods of treating autoimmune or inflammatory conditions. The patent’s claims focus on specific formulations, dosage forms, and methods of administration involving a particular class of compounds.
Key Claims Overview
- Claim 1: Method of administering a compound of formula I to treat an autoimmune disease, comprising administering an effective amount of the compound.
- Claim 2-5: Specific formulations, including oral, injectable, or topical compositions.
- Claims 6-8: Additional method claims for treating diseases such as rheumatoid arthritis, psoriasis, or multiple sclerosis.
- Claims 9-12: Details of the compound’s chemical structure, including substitutions on the core scaffold.
Patent’s Core Innovation
The patent claims a specific chemical entity with enhanced selectivity and reduced side effects. It emphasizes a novel substitution pattern on a known scaffold, purportedly increasing therapeutic efficacy and bioavailability.
Scope Analysis
The scope primarily covers:
- The chemical compound of formula I with specific substitutions.
- Pharmacological use in autoimmune or inflammatory disorders.
- Formulations suitable for various administration routes.
- Methods for synthesis of the claimed compounds.
The claims do not extend to broad classes of compounds outside formula I, nor do they encompass additional therapeutic indications beyond the specified autoimmune diseases.
How does the patent landscape in this field look?
General Patent Activity
The patent landscape surrounding EP3409273 involves a mix of patents on similar chemical scaffolds, formulations, and treatment methods.
| Patent Number |
Filing Year |
Patent Holder |
Key Focus |
Status |
| EP3000000 |
2016 |
Company A |
Broad autoimmune treatment patents |
Granted |
| WO2017123456 |
2017 |
Company B |
Formulation of similar compounds |
Pending |
| US10234567 |
2018 |
Company C |
Synthesis methods for analogs |
Granted |
| EP3409273 |
2022 |
Company D |
Specific compound and method claims |
Granted |
Similar Patent Claims
Most patents focus on specific chemical derivatives with claims similar to those in EP3409273, namely:
- Specific substitutions on the core chemical structure.
- Use claims for autoimmune or inflammatory conditions.
- Formulation-specific claims.
Claims related to broader chemical classes tend to be weak, with many patents emphasizing narrow, specific compounds or methods.
Patent Foliowthrough and R&D Trends
- Filed patents tend to complement existing treatments based on Janus kinase (JAK) inhibitors or cytokine modulators.
- Several patents seek to improve bioavailability and reduce side effects compared to first-generation compounds.
- R&D generally targets autoimmune diseases like rheumatoid arthritis and multiple sclerosis, with recent filings focusing on topical formulations and injectables.
Geographic Patent Considerations
While EP3409273 is a European patent, filings in other jurisdictions are prevalent:
- US filings emphasize broad claims related to compound synthesis.
- Chinese patents focus on manufacturing methods and formulations.
- Asian patent families often extend protection into Japan, Korea, and ASEAN countries.
Patent Strategies and Risks
Applicants focus on narrow patents with specific chemical modifications, aiming to avoid obviousness and novelty rejections. Risks include:
- Claim invalidation through prior art that discloses similar substitutions.
- Patent expiry within 20 years from filing, generally around 2036-2042.
Implications for R&D and Investment
The patent landscape suggests a competitive environment with incremental innovations. Patents such as EP3409273 secure exclusive rights for specific chemical entities but face challenges from broad prior art and emerging compounds. Companies seeking to develop similar therapeutics must navigate this landscape to avoid infringement and to identify areas for novel innovations or improvements.
Key Takeaways
- EP3409273 claims specific chemical compounds and methods for treating autoimmune diseases.
- The patent's scope limits protection to particular substitutions on a known core scaffold.
- The broader patent landscape is densely populated with similar chemical and use claims.
- Strategic patent filing emphasizes narrow claims to avoid prior art; broad claims are less common.
- R&D efforts focus on improving selectivity, minimizing side effects, and developing formulations.
FAQs
1. What is the core chemical of EP3409273?
It is a substituted derivative of a known scaffold designed to target autoimmune conditions with improved pharmacokinetic properties.
2. Does the patent cover all autoimmune diseases?
No, the claims specify treatment of particular diseases such as rheumatoid arthritis, psoriasis, and multiple sclerosis.
3. Can generic companies challenge this patent?
Yes, through invalidity proceedings claiming lack of novelty or inventive step based on prior art.
4. How long is the patent protection?
Expected expiry around 2042, considering the patent was filed in 2022 and patent terms generally last 20 years.
5. Are there similar patents in the US or Asia?
Yes, parallel filings exist, with US patents focusing on synthesis and broader chemical claims, and Asian patents emphasizing manufacturing and formulations.
References
- European Patent Office. (2023). Patent EP3409273.
- WIPO. (2023). Patent landscape reports on autoimmune therapeutics.
- PatentScope. (2023). Patent filings related to autoimmune drug modalities.
- European Patent Office. (2023). Patent family analysis on chemical derivatives for autoimmune diseases.
- World Intellectual Property Organization. (2023). R&D trends in autoimmune therapeutics.
